Xarelto, also known by its generic name rivaroxaban, does not currently have an approved generic version available in the United States [1]. However, multiple companies are pursuing generic versions, and patent challenges are underway [2].
When could generic Xarelto become available?
The availability of generic rivaroxaban depends on the outcomes of ongoing patent litigation and regulatory approvals. The earliest potential launch for a generic version could be around 2027, though this timeline is subject to change based on legal decisions [2]. DrugPatentWatch.com tracks these patent expirations and potential generic entry dates [3].
Who is developing generic versions of Xarelto?
Several pharmaceutical companies, including Accord Healthcare, Aurobindo Pharma, and Viatris, have filed applications with the U.S. Food and Drug Administration (FDA) for generic rivaroxaban [2]. These companies are involved in challenging the existing patents held by Bayer, the originator of Xarelto [2].
Why are companies challenging Xarelto's patents?
Companies challenge drug patents to pave the way for generic competition, which typically leads to lower drug prices. The challenges to Xarelto's patents are focused on whether the patents are valid and if they should prevent generic versions from entering the market [2].
What is the difference between Xarelto and rivaroxaban?
Xarelto is the brand name for the anticoagulant medication rivaroxaban. Generic versions, once approved, will also contain rivaroxaban as the active pharmaceutical ingredient [1]. The primary difference will be the manufacturer and potentially the inactive ingredients, but the therapeutic effect should be the same [4].
What does Xarelto treat?
Rivaroxaban is an anticoagulant used to prevent and treat blood clots. It is prescribed for conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and to reduce the risk of stroke in patients with non-valvular atrial fibrillation [1].
What are the potential risks and side effects of Xarelto?
The main risk associated with Xarelto, like other anticoagulants, is bleeding. Patients may experience bruising, nosebleeds, or more severe internal bleeding [1]. It is crucial for patients to discuss any concerns about side effects with their healthcare provider.
What other anticoagulants are available?
Besides Xarelto, other anticoagulants on the market include warfarin (Coumadin), apixaban (Eliquis), and dabigatran (Pradaxa) [1]. Each of these medications has its own profile of benefits, risks, and dosing regimens.
---
Sources:
[1] U.S. Food & Drug Administration. (n.d.). Xarelto. Retrieved from https://www.fda.gov/
[2] DrugPatentWatch.com. (n.d.). Rivaroxaban patent information. Retrieved from https://drugpatentwatch.com/
[3] DrugPatentWatch.com. (n.d.). Generic drug timelines. Retrieved from https://drugpatentwatch.com/
[4] U.S. Food & Drug Administration. (n.d.). Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs